Pradžia › Imunoblastinė limfadenopatija › New York
Imunoblastinė limfadenopatija klinikiniai tyrimai New York
5 tyrimai dėl Imunoblastinė limfadenopatija ieško dalyvių vietose New York.
Miestai New York
Oficialus tyrimo tekstas (anglų kalba)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- ir dar 5
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06561048A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, New York
- Clinical Trial Site, New York
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT06393738A Registry for People With T-cell Lymphoma
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Weill Cornell Medical Center (Data Collection Only), New York
- ir dar 2
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-05-20 · NCT05978141Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Columbia University, New York
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-22 · NCT04234048Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.